| Literature DB >> 35386918 |
Cathryn T Lee1, Iazsmin Bauer Ventura2, E Kate Phillips3, Amy Leahy1, Renea Jablonski1, Steven Montner4, Jonathan H Chung4, Rekha Vij1, Ayodeji Adegunsoye1, Mary E Strek1.
Abstract
Introduction: Occupational risk factors for interstitial lung disease (ILD) are a remediable aspect of this progressive pulmonary disorder. The association between firefighting and ILD is unknown. Our objective was to assess the characteristics of firefighters with ILD from a large single-center ILD registry.Entities:
Keywords: case series; firefighting; interstitial lung disease; interstitial lung disease risk; occupational exposure
Year: 2022 PMID: 35386918 PMCID: PMC8977739 DOI: 10.3389/fmed.2022.864658
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Cohort characteristics.
|
|
|
| |||
|---|---|---|---|---|---|
| Age, mean ± SD | 63 (11) | Ever Smoker, | 13 (68%) | Autoantibodies, | 10 (53%) |
| Male, | 19 (100%) | Pack years, median (IQR) | 15 (0–40) | ANA>1:320 | 6 (32%) |
| Race, | Secondhand smoke, | 5 (26%) | SSA | 2 (11%) | |
| White | 16 (84%) | Volunteer firefighter, | 3 (16%) | Other | 5 (26%) |
| Black | 3 (16%) | Years worked, median (IQR) | 28 (20–39) | ILD diagnosis, | |
| Asian | 0 (0%) | Hospitalized after fire, | 5 (26%) | IPF | 10 (53%) |
| Family history of ILD, | 0 (0%) | Still firefighting, | 3 (16%) | CTD-ILD | 4 (21%) |
| Family history of CTD, | 4 (21%) | Other work exposures, | 8 (42%) | CPFE | 3 (17%) |
| CTD diagnosis, | Construction | 4 (21%) | Unclassifiable | 1 (5%) | |
| MCTD | 1 (5%) | Metal Work | 2 (11%) | Sarcoidosis | 1 (5%) |
| Autoimmune myositis | 2 (11%) | Other | 3 (16%) | Pathology, | |
| ANCA vasculitis | 1 (5%) | Hobby exposures, | 6 (32%) | UIP | 2 (11%) |
| Comorbidities, | Bird or mold exposures, | 7 (37%) | HP | 1 (5%) | |
| CAD | 10 (53%) | UIP+OP | 2 (11%) | ||
| COPD | 4 (21%) | FVC %pred | 72 (18) | ||
| Diabetes Mellitus | 2 (11%) | DLCO | 51 (16) | ||
| GERD | 14 (74%) | Death | 3 (16%) | ||
| Lung Transplantation | 2 (11%) |
ILD, interstitial lung disease; CTD, connective tissue disease; MCTD, mixed connective tissue disease; ANCA, Antineutrophil Cytoplasmic Antibodies; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; ANA, antinuclear antibodies; SSA, Sjogren's syndrome related antigen A autoantibodies; IPF, idiopathic pulmonary fibrosis; CPFE, combined pulmonary fibrosis and emphysema; UIP, usual interstitial pneumonia; HP, hypersensitivity pneumonitis; OP, organizing pneumonia; FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide.